Deciphera Pharmaceuticals, Inc. operates as a biotechnology company. The Company discovers and develops kinase inhibitor treatments for various type of cancer diseases including gastrointestinal, stromal tumors, advance systemic mastocytosis, gliomas, and other solid tumors. Deciphera Pharmaceuticals serves patients globally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Deciphera Pharmaceuticals (DCPH US)

Current Report (Form 8-K | Period ending 2024-06-11)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

SC14D9C | Written communication by the subject company relating to a third party tender offer

SC14D9C | Written communication by the subject company relating to a third party tender offer

SC14D9C | Written communication by the subject company relating to a third party tender offer

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)